Correlation of adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations

Cheng, Aristine; Hsieh, Ming‐Ju; Chang, Sui‐Yuan; Ieong, Si‐Man; Cheng, Chien-Yu; Sheng, Wang‐Huei; Chang, Shan-Chwen

doi:10.1016/j.jfma.2022.12.002

Cited by 7 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are a few other reports examining the association between reactogenicity to SARS-CoV-2 vaccination and subsequent nAB, but interpretability is limited due to low samples sizes (4 to 8 per condition), 22 the analysis only of nAB trajectories over time, 23 which are confounded by absolute levels given that higher decay rates correlate with higher initial levels, 11 and the use of a mixed sample of mRNA and adenoviral vector vaccine recipients. 24 There are several key strengths of our study compared to the previous large studies. [8][9][10] Firstly, neither of the two studies that included BNT162b2 recipients examined individual symptoms as predictors of nAB.…”

Section: Discussionmentioning

confidence: 93%

“…Indeed, in the present study, we show several predictive relationships that are stronger or only significant for predicting the 6-month rather than 1-month outcome. There are a few other reports examining the association between reactogenicity to SARS-CoV-2 vaccination and subsequent nAB, but interpretability is limited due to low samples sizes (4 to 8 per condition) (18), the analysis only of nAB trajectories over time (19), which are confounded by absolute levels given that higher decay rates correlate with higher initial levels (11), and the use of a mixed sample of mRNA and adenoviral vector vaccine recipients (20).…”

Section: Discussionmentioning

confidence: 99%

“…By contrast, the presence of at least one systemic symptom was associated with higher nAB at 12-19 days after dose two (10) and at 54 days after dose three (9). There are a few other reports examining the association between reactogenicity to SARS-CoV-2 vaccination and subsequent nAB, but interpretability is limited due to low samples sizes (4 to 8 per condition) (19), the analysis only of nAB trajectories over time (20), which are confounded by absolute initial levels (11), and the use of a mixed sample of mRNA and adenoviral vector vaccine recipients (21).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

The more symptoms the better? Covid-19 vaccine side effects and long-term neutralizing antibody response

Dutcher,

Epel,

Mason

et al. 2023

Preprint

View full text Add to dashboard Cite

Protection against SARS-CoV-2 wanes over time, and booster uptake has been low, in part because of concern about side effects. We examined the relationships between local and systemic symptoms, biometric changes, and neutralizing antibodies (nAB) after mRNA vaccination. Data were collected from adults (n = 364) who received two doses of either BNT162b2 or mRNA-1273. Serum nAB concentration was measured at 1 and 6 months post-vaccination. Daily symptom surveys were completed for six days starting on the day of each dose. Concurrently, objective biometric measurements, including skin temperature, heart rate, heart rate variability, and respiratory rate, were collected. We found that certain symptoms (chills, tiredness, feeling unwell, and headache) after the second dose were associated with increases in nAB at 1 and 6 months post-vaccination, to roughly 140-160% the level of individuals without each symptom. Each additional symptom predicted a 1.1-fold nAB increase. Greater increases in skin temperature and heart rate after the second dose predicted higher nAB levels at both time points, but skin temperature change was more predictive of durable (6 month) nAB response than of short-term (1 month) nAB response. In the context of low ongoing vaccine uptake, our convergent symptom and biometric findings suggest that public health messaging could seek to reframe systemic symptoms after vaccination as desirable.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The more symptoms the better? Covid-19 vaccine side effects and long-term neutralizing antibody response

Dutcher,

Epel,

Mason

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…An association between the magnitude of the side effects of anti-SARS-CoV-2 vaccination, especially fever, and the anti-SARS-CoV-2 antibodies, especially upon the first vaccine inoculation, has been described in the literature [ 40 , 41 , 42 ]. However, the lack of side effects did not mean an absence of a protective antibody response [ 43 ].…”

Section: Discussionmentioning

confidence: 99%

Association of the Magnitude of Anti-SARS-CoV-2 Vaccine Side Effects with Sex, Allergy History, Chronic Diseases, Medication Intake, and SARS-CoV-2 Infection

Said,

Al-Rubkhi,

Jaju

et al. 2024

Vaccines

View full text Add to dashboard Cite

Vaccination provides the best protection against the increasing infections of SARS-CoV-2. The magnitude and type of anti-SARS-CoV-2 vaccine side effects (SEs) depend on parameters that are not fully understood. In this cross-sectional study, the associations between different anti-SARS-CoV-2 vaccine SEs and age, sex, the presence of chronic diseases, medication intake, history of allergies, and infections with SARS-CoV-2 were investigated. Our survey used the Google platform and had 866 participants, contacted through e-mails, social media and chain referral sampling (margin of error ≈ 4.38%, 99% confidence). More than 99% of the participants received the BNT162b2 and ChAdOx1-S vaccines. Being female, having chronic diseases, taking medicines routinely and the presence of a SARS-CoV-2 infection (p < 0.05) were associated with strong SEs after the BNT162b2 vaccine second dose. Having a history of allergies and a female sex (p < 0.01) were associated with strong SEs after the ChAdOx1-S vaccine second dose. Furthermore, the results reveal, for the first time, the associations between having a history of allergies, chronic diseases, medication usage, and SEs of a strong magnitude for the BNT162b2 and ChAdOx1-S vaccines. Additionally, this study supports the association of the female sex and infection with SARS-CoV-2 with an increased potential of developing stronger SEs with certain anti-SARS-CoV-2 vaccines.

show abstract

“…This phenomenon was previously seen in a study showing that a third-dose Ad5-nCoV booster increased antibody levels regardless of age 32 . Vaccine reactogenicity is characterized by inflammatory responses of the humoral and cellular immune systems and can result in vaccine-related adverse reactions 33 . There are therefore concerns about the correlations between adverse effects and antibody responses following COVID-19 vaccinations.…”

Section: Discussionmentioning

confidence: 99%

Safety and immunogenicity of Ad5-nCoV immunization after three-dose priming with inactivated SARS-CoV-2 vaccine in Chinese adults

Zhang

et al. 2023

Nat Commun

View full text Add to dashboard Cite

Data on the safety and immunity of a heterologous booster (fourth dose) after three-doses of inactivated SARS-CoV-2 vaccine in Chinese adults are limited. We evaluate the safety and immunogenicity of Ad5-nCoV in a randomized, double-blind, parallel-controlled phase 4 clinical trial in Zhejiang, China (NCT05373030). Participants aged 18–80 years (100 per group), administered three doses of inactivated SARS-CoV-2 vaccine ≥6 months earlier, are enrolled and randomized 1:1 into two groups, which are administered intramuscular Ad5-nCoV or inactivated SARS-CoV-2 vaccine (CoronaVac or Covilo). All observed adverse reactions are predictable and manageable. Ad5-nCoV elicits significantly higher RBD-specific IgG levels, with a geometric mean concentration of 2924.0 on day 14 post-booster, 7.8-fold that of the inactivated vaccine. Pseudovirus-neutralizing antibodies to Omicron BA.4/5 show a similar pattern, with geometric mean titers of 228.9 in Ad5-nCoV group and 65.5 in inactivated vaccine group. Ad5-nCoV booster maintains high antibody levels on day 90, with seroconversion of 71.4%, while that of inactivated vaccine is 5.2%, almost pre-booster levels. A fourth Ad5-nCoV vaccination following three-doses of inactivated SARS-CoV-2 vaccine is immunogenic, tolerable, and more efficient than inactivated SARS-CoV-2 vaccine. Ad5-nCoV elicits a stronger humoral response against Omicron BA.4/5 and maintains antibody levels for longer than homologous boosting.

show abstract

Correlation of adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations

Cited by 7 publications

References 9 publications

The more symptoms the better? Covid-19 vaccine side effects and long-term neutralizing antibody response

The more symptoms the better? Covid-19 vaccine side effects and long-term neutralizing antibody response

Association of the Magnitude of Anti-SARS-CoV-2 Vaccine Side Effects with Sex, Allergy History, Chronic Diseases, Medication Intake, and SARS-CoV-2 Infection

Safety and immunogenicity of Ad5-nCoV immunization after three-dose priming with inactivated SARS-CoV-2 vaccine in Chinese adults

Contact Info

Product

Resources

About